<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721341</url>
  </required_header>
  <id_info>
    <org_study_id>SABR-COMET 10</org_study_id>
    <nct_id>NCT03721341</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors</brief_title>
  <acronym>SABR-COMET 10</acronym>
  <official_title>A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Palma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amsterdam University Medical Centre, VUmc Site</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Cancer - Centre for the North</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beaston West of Scotland Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with a limited oligometastatic burden (cancer has spread but is not yet
      considered metastatic), emerging evidence suggests that treatment of all sites of disease
      with ablative therapies can improve patient outcomes, including overall- and progression-free
      survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10
      metastatic deposits appears promising, yet it is unclear if all patients with greater than 3
      oligometastatic lesions benefit from ablative therapies in terms of improved Overall Survival
      (OS), Progression Free Survival (PFS), or quality of life. The purpose of this study is to
      assess the impact of SABR, compared to standard of care treatment, on overall survival,
      oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10
      metastatic lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival at Study Completion</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
    <description>Time from randomization to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>At approximately year 3, and end of year 6 (study completion)</time_frame>
    <description>Time from randomization to disease progression at any site or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to development of new metastatic lesions</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
    <description>New metastatic lesions will be detected using computed tomography, magnetic resonance imaging, and/or bone scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the Functional Assessment of Cancer Therapy- General (FACT-G) questionnaire</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the EuroQOL Group EQ-5D-5L questionnaire</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>End of years 1, 2, 3, 4, 5, and 6 (study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at midpoint of Study</measure>
    <time_frame>At approximately year 3 (midpoint)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Metastatic Tumors</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative Radiation</intervention_name>
    <description>Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <other_name>Palliative Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy may be given as indicated.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>Immunotherapy may be given as indicated.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormones</intervention_name>
    <description>Hormones may be given as indicated.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Observation only is acceptable if this is the standard practice.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy</intervention_name>
    <description>Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).</description>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Willing to provide informed consent

          -  Karnofsky performance score greater than 60

          -  Life expectancy greater than 6 months

          -  Histologically confirmed malignancy with metastatic disease detected on imaging.
             Biopsy of metastasis is preferred, but not required.

          -  Controlled primary tumor defined as: at least 3 months since original tumor treated
             definitively, with no progression at primary site

          -  Total number of metastases 4-10

          -  All sites of disease can be safely treated based on a pre-plan

        Exclusion Criteria:

          -  Serious medical comorbidities precluding radiotherapy. These include interstitial lung
             disease in patients requiring thoracic radiation, Crohn's disease in patients where
             the GI tract will receive radiotherapy, and connective tissue disorders such as lupus
             or scleroderma.

          -  For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or
             C)

          -  Substantial overlap with a previously treated radiation volume. Prior radiotherapy in
             general is allowed, as long as the composite plan meets dose constraints herein. For
             patients treated with radiation previously, biological effective dose calculations
             should be used to equate previous doses to the tolerance doses listed below. All such
             cases must be discussed with one of the study PIs.

          -  Malignant pleural effusion

          -  Inability to treat all sites of disease

          -  Any single metastasis greater than 5 cm in size.

          -  Any brain metastasis greater than 3 cm in size or a total volume of brain metastases
             greater than 30 cc.

          -  Metastasis in the brainstem

          -  Clinical or radiologic evidence of spinal cord compression

          -  Dominant brain metastasis requiring surgical decompression

          -  Metastatic disease that invades any of the following: GI tract (including esophagus,
             stomach, small or large bowel), mesenteric lymph nodes, or skin

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Palma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suresh Senan, MRCP, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam University Medical Centre, VUmc Site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Olson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer - Centre for the North</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Harrow, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaston West of Scotland Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Palma, MD</last_name>
    <phone>519-685-8650</phone>
    <email>David.Palma@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Regional Cancer Program of the Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Palma, MD</last_name>
      <phone>519-685-8650</phone>
      <email>David.Palma@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>David Palma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners-Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ricard</last_name>
      <phone>705-522-6237</phone>
      <phone_ext>2615</phone_ext>
      <email>laricard@hsnsudbury.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Pearce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal-CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trudel, RN</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>11181</phone_ext>
      <email>diane.dt.trudel.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Lafleur</last_name>
      <phone>514-890-8000</phone>
      <email>chantal.lafleur.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Houda Bahig</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Wong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>David Palma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

